BriaCell Therapeutics Corp.
Description
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
About
CEO
Dr. William V. Williams M.D.
Employees
16
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNCM
Address
Bellevue Centre, West Vancouver, BC V7T 2X1, Canada
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Dec 16, 2025 | — | — | — | — |
| Oct 28, 2025 | — | — | — | — |
| Jun 13, 2025 | — | — | — | — |
| Mar 18, 2025 | — | — | — | — |
| Dec 17, 2024 | -0.08 | -0.22 | -0.14 | 175.00% |
Earnings estimate
|
Current Quarter
(Jan 2025)
|
Next Quarter
(Apr 2025)
|
Current Year
(Jul 2025)
|
Next Year
(Jul 2026)
|
|
|---|---|---|---|---|
| Number of analysts | 0 | 0 | 0 | 0 |
| Average estimate | 0.00 | 0.00 | 0.00 | 0.00 |
| Low estimate | 0.00 | 0.00 | 0.00 | 0.00 |
| High estimate | 0.00 | 0.00 | 0.00 | 0.00 |
| Last year EPS | — | — | — | — |
[stock_revenue_estimate]
Growth estimates
Current qtr (Jan 2025)
—
Next qtr. (Apr 2025)
—
Current year (Jul 2025)
—
Next year (Jul 2026)
—
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2024 | |
|---|---|
| Fiscal date | 2024-07-31 |
| Total reported revenue | — |
| Cost of revenue | — |
| Gross profit | — |
| Operating expense | |
| Research & development | 27.18M |
| Selling general and admin | 6.15M |
| Other operating expenses | — |
| Operating income | -33.33M |
| Non operating interest income | |
| Income | 288,018 |
| Expense | — |
| Other income expense | 28.11M |
| Pretax income | -4.93M |
| Tax provision | — |
| Net income | -4.93M |
| Basic EPS | -0.29 |
| Diluted EPS | -0.29 |
| Basic average shares | 16.45M |
| Diluted average shares | 16.45M |
| EBITDA | -61.46M |
| Net income from continuing op. | -4.93M |
| Minority interests | 140,082 |
| Preferred stock dividends | — |
Balance sheet
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Fiscal date | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 | 2020-07-31 |
| Total assets | 5.87M | 27.16M | 42.58M | 58.04M | 375,968 |
| Current assets | |||||
| Cash | — | — | — | 57.27M | 15,294 |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 862,089 | 21.25M | 41.04M | 57.27M | 15,294 |
| Other short term investments | — | — | — | — | — |
| Accounts receivable | — | 18,873 | 24,103 | 12,574 | 16,206 |
| Other receivables | 1.37M | — | — | — | — |
| Inventory | — | — | — | — | — |
| Prepaid assets | 1.42M | 5.68M | 1.28M | 516,891 | 156,697 |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | — | — | — | — | — |
| Non current assets | |||||
| Properties | 456,801 | — | — | — | — |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | — | — | — | — | — |
| Construction in progress | — | — | — | — | — |
| Leases | — | — | — | — | — |
| Accumulated depreciation | -68,626 | — | — | — | — |
| Goodwill | 199,796 | 215,068 | 230,339 | 245,610 | 187,768 |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 199,796 | 215,068 | 230,339 | 245,610 | 187,768 |
| Investments and advances | 418,490 | 2 | 2 | 2 | 1 |
| Other non current assets | — | — | — | — | — |
| Total liabilities | 8.56M | 30.94M | 32.25M | 30.37M | 2.97M |
| Current liabilities | |||||
| Accounts payable | 7.17M | 1.12M | 463,280 | 214,116 | — |
| Accrued expenses | 290,376 | 677,718 | 477,807 | 261,712 | — |
| Short term debt | — | — | — | — | 179,802 |
| Deferred revenue | — | — | — | — | — |
| Tax payable | — | — | — | — | — |
| Pensions | — | — | — | — | — |
| Other current liabilities | — | — | — | — | — |
| Non current liabilities | |||||
| Long term debt | — | — | — | 25,986 | 155,940 |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | 1.10M | 29.14M | 31.31M | 29.79M | — |
| Other non current liabilities | — | — | — | — | 137,891 |
| Shareholders equity | |||||
| Common stock | 72.17M | 69.59M | 65.59M | 54.77M | 8.83M |
| Retained earnings | -85.44M | -80.65M | -60.35M | -29.14M | -13.08M |
| Other shareholders equity | -138,684 | -138,684 | -138,684 | -138,684 | -99,823 |
| Total shareholders equity | -2.68M | -3.78M | 10.33M | 27.67M | -2.59M |
| Additional paid in capital | — | 7.42M | 5.23M | 2.18M | — |
| Treasury stock | — | — | — | — | — |
| Minority interest | -302,522 | — | — | — | — |
Cash flow statement
| 2024 | |
|---|---|
| Operating Activities | |
| Net Income | -4.93M |
| Depreciation | 83,897 |
| Deferred Taxes | — |
| Stock-Based Compensation | 1.80M |
| Other Non-Cash Items | — |
| Accounts Receivable | -732,578 |
| Accounts Payable | 6.05M |
| Other Assets & Liabilities | — |
| Operating Cash Flow | 2.27M |
| Investing Activities | |
| Capital Expenditures | -456,801 |
| Net Intangibles | — |
| Net Acquisitions | -225,000 |
| Purchase of Investments | — |
| Sale of Investments | — |
| Investing Cash Flow | -681,801 |
| Financing Activities | |
| Long-Term Debt Issuance | — |
| Long-Term Debt Payments | — |
| Other Financing Charges | — |
| Financing Cash Flow | 4.42M |
| Other Cash Details | |
| End Cash Position | 862,089 |
| Income Tax Paid | — |
| Interest Paid | — |
| Free Cash Flow | -24.58M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | Nov 30, 2024 | 482 | 2,159 | 0.02% |
Article
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general meeting of shareholders of the Company (the “Shareholders”) for the year ended July 31, 2024 held on February 5, 2025 (the “Meeting”). A total of 36.26% of the Company's issued and outstanding common shares (the “Common Shares”) were voted at the Meeting.
Feb 5, 2025
Article
BriaCell Therapeutics Announces Closing of Public Offering
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced best-efforts public offering of 762,500 common shares at a public offering price of $4.00 per share. The Company received gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, of $3.05 million. The Company relied upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq.
Feb 5, 2025
Article
BRIACELL THERAP (BCTX) Upgraded to Buy: What Does It Mean for the Stock?
BRIACELL THERAP (BCTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Feb 5, 2025
